Jowell Global vs Pomdoctor
JWEL and POM side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JWEL and POM compare
Jowell Global grew revenue faster over the last twelve months (24.1% versus 16.7% for Pomdoctor).
Jowell Global scores higher on the StockData Score (7 against 1 for Pomdoctor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JWEL | POM |
|---|---|---|
| Size and price | ||
| Share price | $1.73 | $1.62 |
| Change, 1 year | −9.3% | −98.3% |
| Change, 5 years | −99.2% | – |
| Beta (5Y) | 0.97 | 1.22 |
| Employees | 166 | 10K |
| StockData Score | ||
| Total score | 7 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 24.1% (better) | 16.7% |
| Revenue growth, 5Y average | 11.2% | – |
| Profitability | ||
| Gross margin | – | 13.1% |
| Operating margin | −3.0% (better) | −29.7% |
| Net margin | −3.8% | – |
| FCF margin | −0.94% (better) | −37.4% |
| Return on equity | −44.3% | – |
| Return on invested capital | −33.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −30.1× |
| Current ratio | 1.68 (better) | 0.35 |
| Piotroski F-score | 3 | – |
| Ownership | ||
| Held by institutions | – | 0.11% |
| Held by insiders | 0.03% | 28.1% |
| Short interest, % of float | 0.37% | – |
Go deeper
- JWEL stock overview
- JWEL income statement
- JWEL valuation and score
- POM stock overview
- POM income statement
- POM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.